View More Recent Stories
-
Cogint (COGT) Misses Q3 EPS by 7c
-
Citi on Cogent (COGT): 'Non Advanced SM Discontinuation Is Old News; Buy on Weakness'
-
H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)
-
Cogent Biosciences (COGT) Announces Pipeline Expansion into KRAS and Poster Presentations
-
Cogent (COGT) PT Raised to $15 at Citi
-
Cogent (COGT) PT Raised to $10 at Baird
-
Cogent (COGT) PT Lowered to $17 at H.C. Wainwright
-
Citi Reiterates Buy Rating on Cogent (COGT)
-
Piper Sandler Reiterates Overweight Rating on Cogent (COGT)
-
Cogint (COGT) Misses Q2 EPS by 3c
-
Cogent Biosciences (COGT) Reports Positive FDA Meeting and Alignment on MS2D2
-
Cogent Biosciences (COGT) Announces Additional Data from Part 1 of SUMMIT Trial Evaluating Bezuclastinib

